| Name | Artemisone |
| Description | Artemisone (BAY 44-9585) is a potent and semi-synthetic antimalarial, inhibits P. falciparum strains (IC50: 0.83 nM). It also is a potent inhibitor of human CMV. |
| In vitro | Artemisone inhibits 3D7 and K1 P. falciparum with IC50 values of 0.88±0.59 nM and 1.23±0.64 nM, respectively. |
| In vivo | Artemisone, when administered subcutaneously at doses of 3, 1, 0.3, and 0.1 mg/kg in conjunction with other antimalarials, demonstrates an enhanced effectiveness against the chloroquine-resistant P. yoelii NS strain[1]. Moreover, it is effective at inhibiting parasitemia in the P. berghei NY susceptible strain, achieving an ED50 of 9.62 mg/kg through the subcutaneous route and 11.67 mg/kg when given orally[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (9.96 mM), Sonication is recommended.
DMSO : 130 mg/mL (323.77 mM), Sonication is recommended.
|
| Keywords | Parasite | P. falciparum | Inhibitor | inhibit | Cytomegalovirus | CMV | Artemisone |
| Inhibitors Related | Flubendazole | Phenytoin sodium | Kojic acid | Urethane | Hydroxychloroquine | Metronidazole | 2-Amino-2-methyl-1-propanol | Doxycycline | L-Lysine | Fenpyroximate | Thymidine | Coumaran |
| Related Compound Libraries | Anti-Parasitic Compound Library | Failed Clinical Trials Compound Library | Bioactive Compound Library | ReFRAME Related Library | Inhibitor Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Anti-Infection Compound Library | Human Metabolite Library |
United States
